Search Results

You are looking at 1 - 10 of 65 items for :

  • "temsirolimus" x
  • Refine by Access: All x
Clear All
Full access

Pablo Maroto, Georgia Anguera, Juan Maria Roldan-Romero, Maria Apellániz-Ruiz, Ferran Algaba, Jacqueline Boonman, Mark Nellist, Cristina Montero-Conde, Alberto Cascón, Mercedes Robledo, and Cristina Rodríguez-Antona

, clinical options are limited, and the median overall survival for patients with chRCC treated with targeted drugs ranges between 25 and 32 months. 1 – 3 The rapamycin analogs everolimus and temsirolimus are effective anticancer drugs that inhibit mTOR

Full access

Juan Francisco Rodríguez-Moreno, María Apellaniz-Ruiz, Juan María Roldan-Romero, Ignacio Durán, Luis Beltrán, Cristina Montero-Conde, Alberto Cascón, Mercedes Robledo, Jesus García-Donas, and Cristina Rodríguez-Antona

Treatment of advanced renal cell carcinoma (RCC) has changed drastically in the past decade. The mTORC1 inhibitors, everolimus and temsirolimus (also known as rapalogs ), have been shown to be key drugs for use in first-line treatment 1 and

Full access

Daniel Y. C. Heng and Toni K. Choueiri

. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma . N Engl J Med 2007 ; 356 : 2271 – 2281 . 24 Dutcher JP Szczylik C Tannir N . Correlation of survival with tumor histology, age, and prognostic risk group for previously

Full access

Robert A. Figlin, Elizabeth Brown, Andrew J. Armstrong, Wallace Akerley, Al B. Benson III, Harold J. Burstein, David S. Ettinger, Phillip G. Febbo, Matthew G. Fury, Gary R. Hudes, Merrill S. Kies, Eunice L. Kwak, Robert J. Morgan Jr., Joanne Mortimer, Karen Reckamp, Alan P. Venook, Frank Worden, and Yun Yen

mTOR Inhibitors Key Points Four mTOR inhibitors are available for clinical trials: rapamycin and 3 derivatives: temsirolimus, everolimus, and deforolimus. All 4 drugs are structurally similar; differences are related to route of administration and

Full access

scientific peer-review process and are overseen by the ORP. Several NCCN-sponsored studies funded through the grant mechanism are highlighted below. Phase I Study of Perifosine With Temsirolimus for Recurrent Pediatric Solid Tumors Principal

Full access

scientific peer-review process and are overseen by the ORP. Several NCCN-sponsored studies funded through the grant mechanism are highlighted below. A Phase I/II Trial of the Combination of Cisplatin, Cetuximab, and Temsirolimus in Recurrent or

Full access

scientific peer-review process and are overseen by the ORP. Several NCCN-sponsored studies funded through the grant mechanism are highlighted below. A Phase I/II Trial of Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or

Full access

scientific peer-review process and are overseen by the ORP. Several NCCN sponsored-studies funded through the grant mechanism are highlighted below. Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology in Men with Castration

Full access

Josh Lauring, Ben Ho Park, and Antonio C. Wolff

rapamycin and its analogues everolimus and temsirolimus, which allosterically inhibit mTORC1 only, and mTOR kinase inhibitors, which inhibit both mTORC1 and mTORC2. 41 Because rapamycin's discovery and clinical use actually preceded the identification of

Full access

Philip J. Saylor and M. Dror Michaelson

of cell growth . Cell 2000 ; 103 : 253 – 262 . 47 Hudes G Carducci M Tomczak P . Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma . N Engl J Med 2007 ; 356 : 2271 – 2281 . 48 Motzer RJ Escudier B